These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8543977)

  • 21. Omeprazole does not alter plasma methotrexate clearance.
    Whelan J; Hoare D; Leonard P
    Cancer Chemother Pharmacol; 1999; 44(1):88-9. PubMed ID: 10367754
    [No Abstract]   [Full Text] [Related]  

  • 22. The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972.
    Jaffe N
    Clin Orthop Relat Res; 2005 Sep; 438():19-21. PubMed ID: 16131864
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
    Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
    J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nuclear medicine prediction of histologic tumor response of osteosarcoma].
    Knop J; Delling G; Salzer-Kuntschik M; Berberich R; Feine U; Feistel H; Ladenstein R; Müller-Schauenburg W; Schober O; Szabo Z
    Klin Padiatr; 1989; 201(4):285-92. PubMed ID: 2674533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study.
    Macro M; Bouvard G; Le Gangneux E; Colin T; Loyau G
    Rev Rhum Engl Ed; 1995 Feb; 62(2):99-104. PubMed ID: 7600079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. For Patients With Cancer, Cure Is Not Enough.
    Effinger KE; Link MP
    JAMA Oncol; 2016 Feb; 2(2):176-8. PubMed ID: 26584335
    [No Abstract]   [Full Text] [Related]  

  • 27. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
    Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
    Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
    El-Mabhouh AA; Mercer JR
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1240-8. PubMed ID: 18265977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accumulation of methotrexate in human tissues following high-dose methotrexate therapy.
    Iqbal MP
    J Pak Med Assoc; 1998 Nov; 48(11):341-3. PubMed ID: 10323057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and antitumor activity of a polymeric derivative of methotrexate.
    Zhou G; Cheng X; Wu S; Jiang X; Shi X; Chen J; Zhang J; Zhao J
    Am J Med Sci; 2012 Oct; 344(4):294-9. PubMed ID: 22885620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive outcomes of children with osteosarcoma treated with methotrexate.
    Shima H; Sato S; Takimoto T; Sakai M; Hashida N; Isshiki K; Shimada H
    Pediatr Int; 2023 Jan; 65(1):e15487. PubMed ID: 36799122
    [No Abstract]   [Full Text] [Related]  

  • 33. [The effect of chemotherapy on the retention of 99mTc-methylenediphosphonate by the osteogenic sarcoma of the mouse (author's transl)].
    Senekowitsch R; Kriegel H
    Nuklearmedizin; 1980 Aug; 19(4):200-5. PubMed ID: 6937874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals.
    Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
    J Nucl Med; 1980 Oct; 21(10):961-6. PubMed ID: 6252298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 99mTc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content.
    Domstad PA; Coupal JJ; Kim EE; Blake JS; DeLand FH
    Radiology; 1980 Jul; 136(1):209-11. PubMed ID: 6446106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methotrexate-ciprofloxacin interaction: report of two cases of severe intoxication].
    Dalle JH; Auvrignon A; Vassal G; Leverger G; Kalifa C
    Arch Pediatr; 2001 Oct; 8(10):1078-81. PubMed ID: 11683100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
    Fujimoto T
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose methotrexate is effective in osteosarcoma so what is the problem?
    Cohen IJ
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
    [No Abstract]   [Full Text] [Related]  

  • 39. Technetium-99m phytate as a bone-marrow imaging agent: biodistribution studies in animals: concise communication.
    Hamilton RG; Alderson PO; Mclntyre PA
    J Nucl Med; 1977 Jun; 18(6):563-5. PubMed ID: 859038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.